Navigation Links
BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
Date:9/3/2009

LYNBROOK, N.Y., Sept. 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX(TM) (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine (N. Engl. J. Med. 2009;361:968-79.). The article, entitled "Injectable Collagenase Clostridium Histolyticum for Dupuytren's Contracture" describes the positive results observed in a Phase III trial conducted by BioSpecific's licensee Auxilium Pharmaceuticals, Inc. Dupuytren's disease is a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. The first Phase III study of XIAFLEX in Dupuytren's disease was sponsored and monitored by BioSpecifics, with follow-up and data analysis conducted by Auxilium.

"We are very pleased that the results of the successful CORD 1 study were published in this premier medical journal," stated Thomas L. Wegman, President of BioSpecifics. "The details of the study provided in the article further support our view and enthusiasm for the potential benefits of XIAFLEX as a treatment for Dupuytren's disease, and we look forward to the upcoming review by the Arthritis Advisory Committee to the Food and Drug Administration on September 16."

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion Group, a ... BioRx, MedPro Rx, and XAS Infusion Suites. To learn ... ... Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... continue to build on the work we have done, we are ...
(Date:12/7/2016)... PARK, Kan. , Dec. 7, 2016   Rx ... of West Virginia and its Public Employees Insurance ... plan members access to their innovative healthcare software, ultimately saving ... partner with PEIA and provide its members with access to ... changes or a more effective, affordable therapy can be found," ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in ... to a study appearing online in the journal Radiology. , Heart disease and brain ... significantly due to the rapidly aging population. Damage to both organs often occurs at ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
(Date:12/7/2016)... ... 07, 2016 , ... AlignLife clinics nationwide are giving back to their communities ... to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to ... the world. , In exchange for generous donations, customers will receive a gift in ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... proud to announce that its fully redesigned website, which launched October 17, 2016, ... a sleek responsive design and easy-to-navigate layout. Visitors and patients can discover the ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From ... Folio: Marketing Awards competition. Live From won in the Use of Social Media ... ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
Breaking Medicine News(10 mins):